Allianz Asset Management
VIR icon

Allianz Asset Management’s Vir Biotechnology VIR Stock Holding History

Allianz Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-205,125
Closed -$1.24M – 2111
2025
Q4 		$1.24M Sell
205,125
-79,102
-28% -$471K ﹤0.01% 1662
2025
Q3 		$1.62M Sell
284,227
-43,473
-13% -$222K ﹤0.01% 1578
2025
Q2 		$1.65M Buy
327,700
+19,000
+6% +$102K ﹤0.01% 1535
2025
Q1 		$2M Buy
308,700
+136,751
+80% +$1.22M ﹤0.01% 1488
2024
Q4 		$1.26M Buy
171,949
+99,593
+138% +$786K ﹤0.01% 1580
2024
Q3 		$542K Buy
+72,356
New +$628K ﹤0.01% 1835
2023
Q2 		– Sell
-22,394
Closed -$521K – 2293
2023
Q1 		$521K Buy
+22,394
New +$573K ﹤0.01% 1892
2022
Q2 		– Sell
-30,218
Closed -$777K – 2430
2022
Q1 		$777K Buy
30,218
+418
+1% +$12.4K ﹤0.01% 1970
2021
Q4 		$1.24M Buy
29,800
+5,805
+24% +$227K ﹤0.01% 1810
2021
Q3 		$1.04M Sell
23,995
-2,700
-10% -$117K ﹤0.01% 1913
2021
Q2 		$1.26M Hold
26,695
– – ﹤0.01% 1647
2021
Q1 		$1.37M Buy
26,695
+2,395
+10% +$129K ﹤0.01% 1533
2020
Q4 		$651K Buy
+24,300
New +$790K ﹤0.01% 1580

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Allianz Asset Management's VIR Position: Q1 2026 in Review

Allianz Asset Management sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 205,125 shares — an estimated $1.24M sold.

Allianz Asset Management first reported a position in VIR in Q4 2020 and held it in 13 quarters. The position peaked at $2M in Q1 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Allianz Asset Management reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Allianz Asset Management sold 205,125 Vir Biotechnology shares in Q1 2026, an estimated $1.24M.
  • Allianz Asset Management first reported a position in Vir Biotechnology in Q4 2020 and held it in 13 quarters.
  • Allianz Asset Management's Vir Biotechnology position peaked at $2M in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.